Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts
January 23 2024 - 8:30AM
Business Wire
- The new CRO facility for proteomics services in Newton,
Massachusetts ensures closer proximity to US customers
- Biognosys’ center of excellence for proteomics innovation at
its headquarters near Zurich, Switzerland continues to offer its
entire portfolio of services for discovery, targeted, and
structural proteomics for all regions, including the Americas
Biognosys, a leader in next-generation proteomics solutions for
drug discovery and development, announced today the operational
readiness of its new proteomics facility in Massachusetts. This US
expansion facilitates access to select proteomics contract research
organization (CRO) services for our US biopharma customers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240123705269/en/
Biognosys Newton, Massachusetts facility
entrance (Copyright: Biognosys AG)
The Massachusetts facility will initially focus on
TrueDiscovery® data-independent acquisition (DIA) discovery
proteomics services that offer biopharma researchers
high-throughput proteome profiling with industry-leading depth,
reproducibility, and cost-efficiency, powered by the Bruker timsTOF
mass spectrometry platform. Biognosys also anticipates offering
additional discovery and targeted proteomics services for US
customers to access domestically in the future.
“The opening of our new CRO facility in Massachusetts marks a
milestone in our commitment to making proteomics accessible
globally for life science research and drug development,” commented
Dr. Oliver Rinner, CEO and co-founder of Biognosys.
“We are excited to bring our CRO services closer to our US
customers and enable them to fully leverage the potential of
cutting-edge proteomics for the acceleration of therapeutic
discoveries, development and pharmacoproteomics.”
Dr. Rohan Thakur, President Life Sciences Mass Spectrometry
at Bruker, said: “Offering 4D-Proteomics CRO services from the
inventors of Spectronaut – the leading DIA proteomics software, now
augmented with deep learning – will provide broader access to
proteomics in key research areas such as chemoproteomics,
immunopeptidomics, or plasma proteomics. Proteomics at the depth
and scale of Biognosys’ TrueDiscovery platform will accelerate
insights into the complexity of disease biology and is another step
forward in the post-genomic era of drug discovery and
development.”
In the last 15 years, Biognosys has served US biopharma
companies from its facility near Zurich, pioneering the use of
next-generation DIA proteomics in drug research. By expanding its
presence near the life science cluster in the Boston-Cambridge
area, the company plans to extend its collaborations with
innovative early and late-stage biotech companies in New England
and across the Americas.
Biognosys’ laboratory at its headquarters in Switzerland remains
the company’s center of excellence for proteomics innovation and
offers Biognosys’ complete portfolio of services for discovery,
targeted, and structural proteomics to all regions including the
Americas:
- TrueDiscovery® services for unbiased discovery proteomics from
biofluids, tissues and cells, with applications ranging from
biomarker discovery to mechanism of action studies, phosphorylation
profiling, and immunopeptidome profiling
- TrueSignature® custom targeted proteomics panels for
pharmacodynamic and clinical biomarker monitoring through absolute
protein quantification in clinical trials
- TrueTarget® services for novel drug target identification and
validation powered by Limited Proteolysis Mass Spectrometry
(LiP-MS), a proprietary, patented chemoproteomics technology
co-developed by Biognosys
“Our dual-lab strategy underscores our dedication to providing
leading-edge, accessible proteomics solutions,” said Biognosys’
Chief Officer of Scientific Operations (COSO), Dr. Jakob
Vowinckel. “The synergy between our Swiss and US facilities
allows us to serve diverse customer needs, fostering innovation and
collaborations.”
To offer customers industry-leading solutions for a wide range
of biological applications, Biognosys remains committed to
employing mass spectrometry instruments from multiple vendors in
their research services.
About TrueDiscovery®
The Biognosys TrueDiscovery platform offers integrated
proteomics solutions across the entire drug development
pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM™)
mass spectrometry, an advanced Data Independent Acquisition
(DIA)-based protein quantification technology co-invented and
patented by Biognosys.
TrueDiscovery is the only platform that searches the complete
proteome to quantify thousands of the most relevant proteins,
including an unlimited number of proteoforms. The platform enables
the deepest unbiased profiling of tissue and biofluids proteomes
with unbeatable specificity on a large scale. The generated data
are highly reproducible and easily transferrable to clinical
assays. Studies can be performed in compliance with GCP guidelines.
For more information, visit truediscovery.bio.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the
key to breakthrough discoveries that transform science for better
lives. With our versatile portfolio of next-generation proteomics
solutions, including the TrueDiscovery®, TrueTarget®, and
TrueSignature® research service platforms, our flagship software
Spectronaut®, and the PQ500™ kit, we make the proteome actionable
to empower research, drug development, and clinical
decision-making. Our solutions provide a multi-dimensional view of
protein expression, function, and structure in all biological
species and sample types. Our unique, patented technologies utilize
high-resolution mass spectrometry to quantify thousands of proteins
with industry-leading precision, depth, and throughput. Through our
strategic partnership with Bruker (Nasdaq: BRKR), we make
proteomics globally accessible. For more information, visit
biognosys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240123705269/en/
Media Yves Serroen Head of Marketing and Communications
Phone +41 (0) 44 244 50 07 yves.serroen@biognosys.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024